U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C28H33ClN2.2ClH
Molecular Weight 505.95
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BUCLIZINE HYDROCHLORIDE

SMILES

Cl.Cl.CC(C)(C)C1=CC=C(CN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=C(Cl)C=C4)C=C1

InChI

InChIKey=SDBHDSZKNVDKNU-UHFFFAOYSA-N
InChI=1S/C28H33ClN2.2ClH/c1-28(2,3)25-13-9-22(10-14-25)21-30-17-19-31(20-18-30)27(23-7-5-4-6-8-23)24-11-15-26(29)16-12-24;;/h4-16,27H,17-21H2,1-3H3;2*1H

HIDE SMILES / InChI

Molecular Formula C28H33ClN2
Molecular Weight 433.028
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: https://www.ncbi.nlm.nih.gov/pubmed/22469258 | http://edudrugs.com/B/Bucladin-S.html

Buclizine, a piperazine derivative, is a sedating antihistamine with antimuscarinic and moderate sedative action. The drug is used mainly for its antiemetic action, particularly in the prevention of motion sickness, and in the treatment of migraine in combination with analgesics. The following side/adverse effects have been selected on the basis of their potential clinical significance: drowsiness; Incidence less frequent; blurred vision; dryness of mouth, nose, and throat; headache; nervousness, restlessness, or trouble in sleeping; upset stomach. The following drug interactions have been selected on the basis of their potential clinical significance: alcohol; anticholinergics or other medications with anticholinergic activity; apomorphine.

CNS Activity

Curator's Comment: Buclizine is the drug of the first antihistamine generation.Firstgeneration histamine H1-receptor antagonists readily penetrate the blood brain barrier and produce histamine blockade at histamine H1-receptors in the central nervous system.

Originator

Curator's Comment: https://www.ncbi.nlm.nih.gov/pubmed/22469258

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
BUCLADIN-S

Approved Use

For prevention and treatment of nausea, vomiting, and dizziness associated with motion sickness and vertigo (dizziness caused by other medical problems).
Preventing
BUCLADIN-S

Approved Use

For prevention and treatment of nausea, vomiting, and dizziness associated with motion sickness and vertigo (dizziness caused by other medical problems).
Palliative
Migraleve pink

Approved Use

Treating nausea and headache associated with migraine attacks that are not relieved by paracetamol, ibuprofen or aspirin alone.

Launch Date

1.43251197E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.45 μg/mL
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BUCLIZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
5.22 μg × h/mL
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BUCLIZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
5.3 h
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BUCLIZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.
2010 Dec
Patents

Sample Use Guides

50 mg thirty minutes before travel. Dose may be repeated every four to six hours as needed. Usual adult prescribing limits - up to 150 mg daily.
Route of Administration: Oral
Treatment of MCF-7 cells with different concentrations for 72 h showed that buclizine (IC50: 19.18 ± 5.32 μM) revealed considerable growth inhibition.
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:17:00 UTC 2023
Edited
by admin
on Fri Dec 15 16:17:00 UTC 2023
Record UNII
58FQD093NU
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BUCLIZINE HYDROCHLORIDE
MART.   ORANGE BOOK   USAN   VANDF   WHO-DD  
USAN  
Official Name English
UCB 4445
Code English
NSC-25141
Code English
BUCLIZINE DIHYDROCHLORIDE [MI]
Common Name English
PIPERAZINE, 1-((4-CHLOROPHENYL)PHENYLMETHYL)-4-((4-(1,1-DIMETHYLETHYL)PHENYL)METHYL)-, HYDROCHLORIDE (1:2)
Systematic Name English
SOFTRAN
Brand Name English
BUCLADIN
Brand Name English
BUCLIZINE HYDROCHLORIDE [VANDF]
Common Name English
BUCLIZINE HYDROCHLORIDE [MART.]
Common Name English
BUCLIZINE HYDROCHLORIDE [USAN]
Common Name English
VIBAZINE
Brand Name English
Buclizine hydrochloride [WHO-DD]
Common Name English
LONGIFENE
Brand Name English
PIPERAZINE, 1-((4-CHLOROPHENYL)PHENYLMETHYL)-4-((4-(1,1-DIMETHYLETHYL)PHENYL)METHYL)-, DIHYDROCHLORIDE
Common Name English
BUCLINA
Brand Name English
UCB-4445
Code English
APHILAN
Brand Name English
BUCLODIN
Brand Name English
BUCLIZINE DIHYDROCHLORIDE
MI  
Common Name English
1-(P-TERT-BUTYLBENZYL)-4-(P-CHLORO-.ALPHA.-PHENYLBENZYL)PIPERAZINE DIHYDROCHLORIDE
Common Name English
BUCLIZINE HYDROCHLORIDE [ORANGE BOOK]
Common Name English
BUCLIZINE HCL
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29578
Created by admin on Fri Dec 15 16:17:00 UTC 2023 , Edited by admin on Fri Dec 15 16:17:00 UTC 2023
Code System Code Type Description
EPA CompTox
DTXSID5045091
Created by admin on Fri Dec 15 16:17:00 UTC 2023 , Edited by admin on Fri Dec 15 16:17:00 UTC 2023
PRIMARY
CAS
7139-55-1
Created by admin on Fri Dec 15 16:17:00 UTC 2023 , Edited by admin on Fri Dec 15 16:17:00 UTC 2023
NON-SPECIFIC STOICHIOMETRY
CAS
129-74-8
Created by admin on Fri Dec 15 16:17:00 UTC 2023 , Edited by admin on Fri Dec 15 16:17:00 UTC 2023
PRIMARY
NSC
25141
Created by admin on Fri Dec 15 16:17:00 UTC 2023 , Edited by admin on Fri Dec 15 16:17:00 UTC 2023
PRIMARY
DRUG BANK
DBSALT000197
Created by admin on Fri Dec 15 16:17:00 UTC 2023 , Edited by admin on Fri Dec 15 16:17:00 UTC 2023
PRIMARY
MERCK INDEX
m2744
Created by admin on Fri Dec 15 16:17:00 UTC 2023 , Edited by admin on Fri Dec 15 16:17:00 UTC 2023
PRIMARY Merck Index
PUBCHEM
65463
Created by admin on Fri Dec 15 16:17:00 UTC 2023 , Edited by admin on Fri Dec 15 16:17:00 UTC 2023
PRIMARY
EVMPD
SUB00889MIG
Created by admin on Fri Dec 15 16:17:00 UTC 2023 , Edited by admin on Fri Dec 15 16:17:00 UTC 2023
PRIMARY
SMS_ID
100000091920
Created by admin on Fri Dec 15 16:17:00 UTC 2023 , Edited by admin on Fri Dec 15 16:17:00 UTC 2023
PRIMARY
FDA UNII
58FQD093NU
Created by admin on Fri Dec 15 16:17:00 UTC 2023 , Edited by admin on Fri Dec 15 16:17:00 UTC 2023
PRIMARY
WIKIPEDIA
Bucladin
Created by admin on Fri Dec 15 16:17:00 UTC 2023 , Edited by admin on Fri Dec 15 16:17:00 UTC 2023
PRIMARY
ChEMBL
CHEMBL1201271
Created by admin on Fri Dec 15 16:17:00 UTC 2023 , Edited by admin on Fri Dec 15 16:17:00 UTC 2023
PRIMARY
ECHA (EC/EINECS)
204-962-4
Created by admin on Fri Dec 15 16:17:00 UTC 2023 , Edited by admin on Fri Dec 15 16:17:00 UTC 2023
PRIMARY
NCI_THESAURUS
C65274
Created by admin on Fri Dec 15 16:17:00 UTC 2023 , Edited by admin on Fri Dec 15 16:17:00 UTC 2023
PRIMARY
CHEBI
61193
Created by admin on Fri Dec 15 16:17:00 UTC 2023 , Edited by admin on Fri Dec 15 16:17:00 UTC 2023
PRIMARY
RXCUI
91070
Created by admin on Fri Dec 15 16:17:00 UTC 2023 , Edited by admin on Fri Dec 15 16:17:00 UTC 2023
PRIMARY RxNorm
Related Record Type Details
ENANTIOMER -> RACEMATE
PARENT -> SALT/SOLVATE
ENANTIOMER -> RACEMATE
Related Record Type Details
ACTIVE MOIETY